April 23rd 2024
Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
July 26th 2023
Sarah E. S. Leary, MD, MS, discusses findings from the phase 2 FIREFLY-1 trial in pediatric patients with low-grade glioma.